Immunotherapy and overall survival among older patients with advanced non-small cell lung cancer

Read full text Summarise with VIRAT
Authors: Yasutaka Ihara, Naoyuki Nogami, Megumi Mizutani, Shoichiro Yamamoto, Yuki Shimomura, Takumi Imai
Cited by: 0
References: 36

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Older patients represent the majority of patients with advanced non-small cell lung cancer (NSCLC) but remain under-represented in clinical trials of immune-checkpoint inhibitor (ICI) therapy, leaving the optimal age-specific first-line treatment uncertain. To assess whether the survival benefit of first-line ICI therapy compared to conventional chemotherapy demonstrated in clinical trials extends to older patients with advanced NSCLC in clinical practice. This retrospective cohort study analyzed administrative claims data from Japan between December 2015 and January 2023. To assess whether age modifies the association between immunotherapy as a first-line therapy compared to conventional chemotherapy and overall survival in patients with advanced NSCLC, we conducted multivariable Cox proportional hazards regression treating age as a continuous variable. Among 35,953 patients with advanced NSCLC, 14,560 received ICI therapy (mean [standard deviation] age, 70.3 [9.2] years; 11,669 [80.1%] males), and 21,393 received conventional chemotherapy (mean [standard deviation] age, 70.2 [9.0] years; 16,098 [75.2%] males). ICI therapy was associated with a lower mortality risk than conventional chemotherapy across the examined age range (50–85 years). This association was more pronounced in patients aged 70 years, while the difference was less marked in those aged 60–70 years. Our real-world findings suggest that the survival benefit of ICI therapy demonstrated in clinical trials may extend to older patients with advanced NSCLC. Additionally, the fact that the association between immunotherapy and lower mortality risk varies across ages 50–85 years highlights the importance of age-specific assessments for individualized treatment strategies.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations

Publication details

Journal / source
International Journal of Lung Cancer
Volume
1
Issue
2
Pages
100018–100018
Publication date
28 March 2026
Language
EN